AstraZeneca PLC ADR AZN
-
Actavis (ACT) confirms that an Appeals Court has granted an injunction to AstraZeneca ( AZN ) to enjoin [[ACT]] from further distribution of its generic version of Pulmicort until [[ AZN ]]'s appeal ...
… granted an injunction to AstraZeneca ( AZN ) to enjoin ACT from ..... version of Pulmicort until AZN 's appeal before the ..... following a ruling that AZN 's patent was invalid ..... generic sales to permit AstraZeneca an opportunity to seek …
-
Retirement Portfolio,review
… portfolio is as follows: Dividend stocks: T $45,000, VZ $45,000, NYCB $30,000, Mo $35,000,ED $30,000, and AZN $20,000. Hybrid Funds: Berix $140,000, Vwinx $160,000, Exdax $140,000 Bond funds:Ostix $140,000, Tgcfx …
-
AstraZeneca closes in on site for new home in Cambridge
* New research centre and corporate HQ to cost some $500 mln
-
AstraZeneca : A Dividend Payer With An Attractive Growth Prospect
… pharmaceutical goods offers an excellent growth opportunity. Although there are a number of companies worth investing in, AstraZeneca ( AZN ), the UK's second largest drug maker, is in a great position to offer significant upside in both its share price …
-
AstraZeneca accelerates cancer drug testing
* Final-stage studies on olaparib, selumetinib start in H2
-
Array Biopharma: Measuring The Strength Of This Small-Cap Pharma Stock
By Emerging Equities : Here's a scenario: a company reports a quarterly loss, and on top of that, a bigger loss than the market expected, but within four days of results coming out, the stock gains 4% where it had been losing more than 10% previously. In addition, seven out of eight analysts ...
-
Wall Street Breakfast: Must-Know News
Wall Street Breakfast Editors submit: Top Stories Loeb pushes for Sony spinoff. Daniel Loeb, whose Third Point Capital has a 6.5% stake in Sony ( SNE ) worth some $1.1B, is pushing for a spinoff of the company's entertainment business including the film studio responsible for James Bond blockbuster
-
Shares of Optimer Pharmaceutical ([[OPTR]] +14%) ramped up into the close on reports that AstraZeneca ( AZN ), Astellas Pharma ([[ALPMY.PK]]) and Cubist Pharmaceuticals (CBST) are among the first round ...
Shares of Optimer Pharmaceutical ( OPTR +14% ) ramped up into the close on reports that AstraZeneca ( AZN ), Astellas Pharma ( ALPMY.PK ) and Cubist Pharmaceuticals ( CBST ) are among the first round bidders for the antibiotic manufacturer …
-
New Morningstar Analyst Report - Bristol-Myers Squibb Company
… costs and diversify the risks of clinical and regulatory failure. We believe diabetes drug Onglyza (partnered with AstraZeneca AZN ) represents one of the most important new drug for Bristol. Additionally, anticoagulant Eliquis could potentially …
-
New Morningstar Analyst Report - Myriad Genetics
… therapy to a patient's genetic profile. While there have been several setbacks with PARP inhibitors at Sanofi SNY and AstraZeneca AZN , we think drugs from this class still have potential when targeted to BRCA mutants, adding to the rationale for …